Supervised exercise as good as surgery for intermittent claudication due to iliac artery obstruction

Written By :  Dr. Shravani Dali
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-05-03 15:30 GMT   |   Update On 2022-05-03 15:25 GMT
Advertisement

Both a strategy of primary supervised exercise therapy and primary endovascular revascularisation improve maximum walking distance on a treadmill and disease specific Qol of patients with intermittent claudication due to iliac artery obstruction, according to a recent study published in the European Journal of Vascular and Endovascular Surgery

International guidelines recommend supervised exercise therapy (SET) as primary treatment for all patients with intermittent claudication (IC), yet primary endovascular revascularisation (ER) might be more effective in patients with iliac artery obstruction.

Advertisement

This was a multicentre RCT including patients with intermittent claudication (IC) caused by iliac artery stenosis or occlusion (NCT01385774). Patients were allocated randomly to supervised exercise therapy (SET) or endovascular revascularisation (ER) stratified for maximum walking distance (MWD) and concomitant SFA disease. Primary endpoints were maximum walking distance (MWD) on a treadmill (3.2 km/h, 10% incline) and disease specific quality of life (VascuQol) after one year. Additional interventions during a mean follow up of 5.5 years were recorded.

The results of the study are:

  • Between November 2010 and May 2015, 114 patients were allocated to supervised exercise therapy (SET), and 126 to endovascular revascularisation (ER). The trial was terminated prematurely after 240 patients were included.
  • Compliance with supervised exercise therapy (SET) was 57/114 (50%) after six months.
  • Ten patients allocated to endovascular revascularisation (ER) (8%) did not receive this intervention. One year follow up was complete for 90/114 (79%) supervised exercise therapy (SET) patients and for 104/126 (83%) endovascular revascularisation (ER) patients.
  • The mean maximum walking distance (MWD) improved from 187 to 561 m in SET patients and from 196 to 574 m in endovascular revascularisation (ER) patients (p = .69). VascuQol sumscore improved from 4.24 to 5.58 in SET patients, and from 4.28 to 5.88 in ER patients (p = .048). Some 33/114 (29%) supervised exercise therapy (SET) patients had an endovascular revascularisation (ER) within one year, and 2/114 (2%) surgical revascularisation (SR). Some 10/126 (8%) ER patients had additional endovascular revascularisation (ER) within one year and 10/126 (8%) surgical revascularisation (SR).
  • After a mean of 5.5 years, 49% of supervised exercise therapy (SET) patients and 27% of endovascular revascularisation (ER) patients underwent an additional intervention for intermittent claudication (IC).

Thus, taking into account the many limitations of the SUPER study, both a strategy of primary supervised exercise therapy (SET) and primary endovascular revascularisation (ER) improve maximum walking distance (MWD) on a treadmill and disease specific Qol of patients with intermittent claudication (IC)caused by an iliac artery obstruction. It seems reasonable to start with supervised exercise therapy (SET) in these patients and accept a 30% failure rate, which, of course, must be discussed with the patient. Patients continue to have interventions beyond one year.

Reference:

Editor's Choice – Randomised Clinical Trial of Supervised Exercise Therapy vs. Endovascular Revascularisation for Intermittent Claudication Caused by Iliac Artery Obstruction: The SUPER study by Mark J.W. Koelemay et al. published in the European Journal of Vascular and Endovascular Surgery.

DOI: https://doi.org/10.1016/j.ejvs.2021.09.042


Tags:    
Article Source : European Journal of Vascular and Endovascular Surgery

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News